Treovir, Inc.

Birmingham, AL · Founded 2019 · CIK 0001825493 · Biotech · Private

G207, an oncolytic herpes simplex virus immunotherapy for brain tumors

treovir.com →
Grants
$4.6M
5 awards
Sector median: 1
Raised
$133K
1 Form D · Sep 2020
72 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · Phase II Clinical Trial of G207 HSV To Treat Children with High Grade Gliomas$497,320
Federal grantDepartment of Health and Human Services · Phase II · Phase II Clinical Trial of G207 HSV To Treat Children with High Grade Gliomas$2,613,534
Private capital raisedForm D · SEC$132,584
Federal grantDepartment of Health and Human Services · Phase II · Phase II Clinical Trial of G207 HSV To Treat Children with High Grade Gliomas$611,912
Federal grantDepartment of Health and Human Services · Phase II · Phase II Clinical Trial of G207 HSV To Treat Children with High Grade Gliomas$1,625
Federal grantDepartment of Health and Human Services · Phase II · Phase II Clinical Trial of G207 HSV To Treat Children with High Grade Gliomas$890,765
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1482PROTHERA BIOLOGICS, INC.—$250K
1483Modulate Bio Inc.—$200K
1484Aperta Biosciences, LLC—$175K
1485Treovir, Inc.—$133K
1486APTINYX, INC.—$95M
1487Selva Nexus, Inc.—$50K
1488NOVOBIOTIC PHARMACEUTICALS, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 4 related persons
  • Michael ChristiniDirector · Executive Officer
  • G. GillespieDirector · Executive Officer
  • James MarkertDirector
  • Richard WhitelyDirector

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.